• DOI:10.1136/bmj.m3379
Corpus ID: 221498813

A living WHO guideline on drugs for covid-19

@article{Lamontagne2020ALW,
  title={A living WHO guideline on drugs for covid-19},
  author={F. Lamontagne and T. Agoritsas and H. Macdonald and Y. Leo and J. Diaz and A. Agarwal and J. Appiah and Y. Arabi and L. Blumberg and C. Calfee and B. Cao and M. Cecconi and G. Cooke and J. Dunning and H. Geduld and Patrick O Gee and Hela Manai and D. S. Hui and Seema Kanda and L. Kawano-Dourado and Yae-Jean Kim and N. Kissoon and A. Kwizera and J. H. Laake and F. R. Machado and Nida Qadir and R. Sarin and Yinzhong Shen and Linan Zeng and R. Brignardello-Petersen and L. Lytvyn and R. Siemieniuk and D. Zeraatkar and J. Bartoszko and Long Ge and Brittany J. Maguire and B. Rochwerg and G. Guyatt and P. Vandvik},
  journal={BMJ},
  year={2020},
  volume={370}
}

F. Lamontagne, T. Agoritsas, +36 authors P. Vandvik

Published 2020

Medicine

BMJ

Abstract Clinical question What is the role of drug interventions in the treatment and prevention of covid-19? Recommendations The first version on this living guidance focuses on corticosteroids. It contains a strong recommendation for systemic corticosteroids in patients with severe and critical covid-19, and a weak or conditional recommendation against systemic corticosteroids in patients with non-severe covid-19. Corticosteroids are inexpensive and are on the World Health Organisation list… CONTINUE READING

View on BMJ

bmj.com

Save to Library

Create Alert

Cite

Launch Research Feed